As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
The study evaluated patients with stage III/IV melanoma after complete tumor resection
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
The launch of the study was on the occasion of the International Day of Persons with Disabilities
Subscribe To Our Newsletter & Stay Updated
